Last reviewed · How we verify
Hign dose Daunorubicin
High-dose daunorubicin is a topoisomerase II inhibitor anthracycline that intercalates into DNA and prevents cell division, primarily used in hematologic malignancies.
High-dose daunorubicin is a topoisomerase II inhibitor anthracycline that intercalates into DNA and prevents cell division, primarily used in hematologic malignancies. Used for Acute myeloid leukemia (AML) induction therapy, Acute lymphoblastic leukemia (ALL), High-dose chemotherapy conditioning regimen for hematopoietic stem cell transplantation.
At a glance
| Generic name | Hign dose Daunorubicin |
|---|---|
| Also known as | AD |
| Sponsor | Asan Medical Center |
| Drug class | Anthracycline topoisomerase II inhibitor |
| Target | Topoisomerase II, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Daunorubicin intercalates between DNA base pairs and inhibits topoisomerase II, preventing DNA unwinding and replication. At high doses, it generates reactive oxygen species that cause additional DNA damage and apoptosis. The high-dose formulation is typically used in intensive chemotherapy regimens for acute leukemias and lymphomas, often as part of conditioning therapy or induction treatment.
Approved indications
- Acute myeloid leukemia (AML) induction therapy
- Acute lymphoblastic leukemia (ALL)
- High-dose chemotherapy conditioning regimen for hematopoietic stem cell transplantation
Common side effects
- Cardiotoxicity/cardiomyopathy
- Myelosuppression (neutropenia, thrombocytopenia)
- Mucositis
- Nausea and vomiting
- Alopecia
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hign dose Daunorubicin CI brief — competitive landscape report
- Hign dose Daunorubicin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI